Walgreens Boots Alliance Azioni (NASDAQ: WBA)

Ultime notizie per Walgreens Boots Alliance (NASDAQ:WBA) Azioni

Walgreens Boots Alliance

Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,500 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

DLTR

Scopri perché Walgreens, Dollar General e Dollar Tree potrebbero rappresentare opportunità d&#39;oro per gli investitori.

Perché queste 3 azioni possono essere una miniera d&#39;oro

Dividends

Scopri i 3 titoli con dividendi elevati che gli analisti di Wall Street consigliano per il tuo portafoglio questo mese.

Gli analisti consigliano questi 3 titoli dal dividendo elevato

Walgreens Boots Alliance, Inc. - Common Stock

Walgreens Boots Alliance Inc

WisdomTree Trust WisdomTree Battery Value Chain and Innovation Fund

WALGREEN BOOTS ALLIANCE ORD

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 11.49%</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and cut the price target from $17 to $12 on July 3. This analyst has an accuracy rate of 75%.</li>
<li>RBC Capital analyst Ben Hendrix maintained a Sector Perform rating and slashed the price target from $22 to $13 on July 2. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On Sept. 13, Walgreens Boots Alliance agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act and state regulations.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1">latest WBA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="900" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03072919/image-11.png" alt="" class="wp-image-578386" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03072919/image-11.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03072919/image-11-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03072919/image-11-768x719.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</h3>
<ul>
<li>Dividend Yield: 4.66%</li>
<li>Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and raised the price target from $34 to $35 on Aug. 1. This analyst has an accuracy rate of 63%.</li>
<li>B of A Securities analyst Bryan Spillane maintained a Buy rating and cut the price target from $42 to $38 on July 10. This analyst has an accuracy rate of 64%</li>
<li>Recent News: On July 31, Kraft Heinz reported better-than-expected second-quarter adjusted EPS results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"> latest KHC news</a>.</li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="822" height="797" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03072944/image-2-5.png" alt="" class="wp-image-578387" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03072944/image-2-5.png 822w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03072944/image-2-5-300x291.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03072944/image-2-5-768x745.png 768w" sizes="(max-width: 822px) 100vw, 822px" /></a></figure>
<h3 class="wp-block-heading">Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</h3>
<ul>
<li>Dividend Yield: 4.52%</li>
<li>Goldman Sachs analyst Bonnie Herzog maintained a Buy rating and raised the price target from $126 to $140 on Sept. 26. This analyst has an accuracy rate of 71%.</li>
<li>Barclays analyst Gaurav Jain maintained an Overweight rating and increased the price target from $130 to $145 on Sept. 9. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: Philip Morris International is expected to report results for its fiscal third quarter on Oct. 22.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1">trend in PM stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03073026/image-12.png" alt="" class="wp-image-578388" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03073026/image-12.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03073026/image-12-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03073026/image-12-768x716.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41156151/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Analyst Ratings

Wall Street's Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields

Investors with a lot of money to spend have taken a bullish stance on Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WBA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Walgreens Boots Alliance.
This isn't normal.
The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $317,948, and 6 are calls, for a total amount of $251,974.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.5 to $12.5 for Walgreens Boots Alliance over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Walgreens Boots Alliance options trades today is 8118.0 with a total volume of 10,303.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Walgreens Boots Alliance's big money trades within a strike price range of $7.5 to $12.5 over the last 30 days.
<h3>Walgreens Boots Alliance Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727454768_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$12.50</td>
<td>$180.0K</td>
<td>554</td>
<td>506</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.33</td>
<td>$2.32</td>
<td>$2.33</td>
<td>$10.00</td>
<td>$87.6K</td>
<td>14.5K</td>
<td>886</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$2.93</td>
<td>$2.9</td>
<td>$2.93</td>
<td>$10.00</td>
<td>$58.7K</td>
<td>280</td>
<td>307</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.62</td>
<td>$0.6</td>
<td>$0.62</td>
<td>$10.00</td>
<td>$55.4K</td>
<td>4.3K</td>
<td>3.1K</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.35</td>
<td>$2.31</td>
<td>$2.35</td>
<td>$10.00</td>
<td>$50.2K</td>
<td>14.5K</td>
<td>240</td>
</tr>
</tbody>
</table>

<h3>About Walgreens Boots Alliance</h3>
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,500 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
In light of the recent options history for Walgreens Boots Alliance, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Walgreens Boots Alliance</h3>
<ul>
<li>Currently trading with a volume of 14,363,721, the WBA's price is up by 1.41%, now at $8.64. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 18 days.</li>
</ul>
<h3>What The Experts Say On Walgreens Boots Alliance</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $12.833333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Walgreens Boots Alliance with a target price of $16. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Walgreens Boots Alliance with a target price of $15. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Walgreens Boots Alliance with a target price of $7. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Walgreens Boots Alliance with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

What the Options Market Tells Us About Walgreens Boots Alliance

WIIM

GDRX

PETS

Shares of pharmacy stocks are trading higher. Costco on its earnings call said pharmacy had the strongest sales percentage increase within ancillary businesses, with a double-digit script count growth, which could possibly be lifting the sector.

U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Friday.
Shares of IonQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) rose sharply during Friday's session after the company announced it signed a $54.5 million contract with the <a href="https://www.benzinga.com/quote/IONQ/news">United States Air Force Research Lab.</a>
IonQ shares surged 20% to $9.67 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares jumped 15.5% to $11.05. Biomea Fusion disclosed that the FDA lifted its clinical hold on BMF-219 in Type 2 and Type 1 diabetes trials. Rodman &amp; Renshaw analyst Tony Butler upgraded Biomea Fusion from Neutral to Buy.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) surged 14.1% to $3.23.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) rose 11.5% to $3.67.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) jumped 11.5% to $9.69. Keybanc analyst Michael Leshock maintained Rocket Lab USA with an Overweight and raised the price target from $8 to $11.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) gained 11.3% to $16.79.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) shares jumped 10.5% to $11.82.</li>
<li>Empire State Realty OP, L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESBA#NYSE">ESBA</a>) gained 8.4% to $11.50.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 8.4% to $16.79.</li>
<li>Dada Nexus Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>) climbed 7% to $1.71.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) gained 6.6% to $6.16.</li>
<li>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) gained 5.7% to $9.01.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41066188/this-hp-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday">This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday</a></li>
</ul>

Intraday Update

Movers

BMEA

CERT

DADA

ESBA

IONQ

MNSO

RKLB

UXIN

IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday

On Wednesday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has urged a federal appeals court to overturn a $183 million judgment stemming from accusations of defrauding Medicaid.
The case, initiated in 2014, alleges that Eli Lilly underreported drug prices to Medicaid, resulting in smaller rebates owed to the program.
Last week,&nbsp;Walgreens Boots Alliance&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40881893/walgreens-agrees-to-106-8m-settlement-over-alleged-false-billing-claims" rel="noreferrer noopener">and state regulations</a>.
The U.S. pharma giant claims it is being wrongfully held liable despite adhering to its interpretation of Medicaid&#8217;s complex rebate requirements.
The claims also highlight that Eli Lilly failed to disclose price increases billed to distributors, which were not reflected in its Medicaid pricing reports.
Reuters noted that Eli Lilly started reporting price increases after a 2017 rule change, though the company claims it had previously informed regulators about its pricing practices without facing any objections.
In 2022, a U.S. District Judge rejected Eli Lilly&#8217;s motion for summary judgment, ruling that its price statements were misleading and allowing the case to proceed. In May 2023, a jury found Eli Lilly responsible for $61 million in damages, which were tripled to $183 million under the federal False Claims Act.
Most recently, Oak Street Health, a subsidiary of&nbsp;CVS Health&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), agreed to settle for $60 million following allegations that it violated the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40945496/cvs-subsidiary-oak-street-health-agrees-to-60m-settlement-in-medicare-kickback-violations" rel="noreferrer noopener">False Claims Act</a>.
The&nbsp;<a target="_blank" href="https://www.justice.gov/opa/pr/oak-street-health-agrees-pay-60m-resolve-alleged-false-claims-act-liability-paying-kickbacks" rel="noreferrer noopener">claims</a> involved paying kickbacks to third-party insurance agents to recruit seniors to its primary care clinics, a practice that led to false Medicare submissions.
The case has garnered attention from major business groups, including the U.S. Chamber of Commerce and Pharmaceutical Research and Manufacturers of America (PhRMA). These organizations argue that upholding the judgment would create uncertainty for regulated companies.
Price Action: LLY stock is trading higher by 1.45% to $928.28 premarket at the last check on Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40955083/holiday-opportunity-macys-plans-to-hire-31-500-seasonal-workers" target="_blank" rel="noreferrer noopener">Holiday Opportunity: Macy&#8217;s Plans To Hire 31,500 Seasonal Workers</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Legal

General

Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules

Wednesday, Oak Street Health, a subsidiary of CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), agreed to settle for $60 million following allegations that it violated the False Claims Act.
The <a target="_blank" href="https://www.justice.gov/opa/pr/oak-street-health-agrees-pay-60m-resolve-alleged-false-claims-act-liability-paying-kickbacks" rel="noreferrer noopener">claims</a> involved paying kickbacks to third-party insurance agents to recruit seniors to its primary care clinics, a practice that led to false Medicare submissions.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/08/40437498/pharmacy-chains-like-cvs-health-walgreens-boots-alliance-confront-shifting-consumer-habits-and-pro" rel="noreferrer noopener">Pharmacy Chains Like CVS Health, Walgreens Boots Alliance Confront Shifting Consumer Habits And Profit Pressures</a>.
The allegations center around Oak Street Health&#8217;s Client Awareness Program, launched in 2020, which aimed to increase membership through third-party insurance agents.
These agents targeted seniors enrolled or eligible for Medicare Advantage (MA) plans, directing them toward Oak Street's services.
In exchange, agents received approximately $200 per referral, incentivizing them to prioritize financial gain over seniors&#8217; best interests.
This behavior violated the Anti-Kickback Statute, which prohibits offering payment to induce patient referrals under federally funded programs like Medicare.
The U.S. Department of Justice (DOJ) claimed that Oak Street Health knowingly submitted false claims to Medicare between September 2020 and December 2022 due to these illegal kickbacks.
"Health care providers that attempt to profit from kickbacks will be held accountable," said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department&#8217;s Civil Division. "We are committed to rooting out illegal practices committed by Medicare Advantage providers, insurance agents and brokers that undermine the interests of federal health care programs and the patients they serve."
Additionally, the settlement resolves claims brought under the whistleblower provisions of the False Claims Act by Joseph Stinson. Stinson will receive $9.9 million as part of the settlement.
Last week, Walgreens Boots Alliance&nbsp;Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)&nbsp;agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40881893/walgreens-agrees-to-106-8m-settlement-over-alleged-false-billing-claims" rel="noreferrer noopener">and state regulations</a>.
Price Action: CVS stock is up 0.27% at $58.58 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40941051/fda-strikes-off-vanda-pharmaceuticals-tradipitant-for-stomach-paralysis-asks-for-additional-studi" target="_blank" rel="noreferrer noopener">FDA Strikes Off Vanda Pharmaceuticals&#8217; Tradipitant For Stomach Paralysis, Asks For Additional Studies</a>.</li>
</ul>
Photo via Shutterstock

CVS Subsidiary Oak Street Health Agrees to $60M Settlement in Medicare Kickback Violations

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 11.09%</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and cut the price target from $17 to $12 on July 3. This analyst has an accuracy rate of 71%.</li>
<li>RBC Capital analyst Ben Hendrix maintained a Sector Perform rating and decreased the price target from $22 to $13 on July 2. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On Friday, Walgreens Boots Alliance agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act and state regulations.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://pro.benzinga.com/dashboard">atest WBA new</a>s.</li>
</ul>
<h3 class="wp-block-heading">B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>)</h3>
Dividend Yield: 8.41%
<ul>
<li>Barclays analyst Brandt Montour maintained an Equal-Weight rating and cut the price target from $10 to $8 on July 19. This analyst has an accuracy rate of 64%</li>
<li>Piper Sandler analyst Michael Lavery maintained a Neutral rating and cut the price target from $9 to $8 on July 11. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Sept. 9, B&amp;G Foods issued notice of full redemption of remaining 5.25% senior notes due 2025.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://pro.benzinga.com/dashboard">trend in BGS stock</a>.</li>
</ul>
<h3 class="wp-block-heading">Altria Group, Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>)</h3>
<ul>
<li>Dividend Yield: 7.89%</li>
<li>Barclays analyst Gaurav Jain maintained an Underweight rating and raised the price target from $43 to $45 on Sept. 9. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Matthew Smith maintained a Buy rating and raised the price target from $50 to $54 on Aug. 1. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Aug. 22, Altria increased its quarterly dividend by 4.1% to $1.02 per share.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in MO shares</a>.</li>
</ul>

<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40877520/if-you-want-steel-you-do-nucor-says-cramer-when-asked-about-gerdau">&#8216;If You Want Steel, You Do Nucor,&#8217; Says Cramer When Asked About Gerdau</a></li>
</ul>

Price Target

Wall Street's Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 7% Dividend Yields

On Friday, Walgreens Boots Alliance Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act <a href="https://www.benzinga.com/general/health-care">and state regulations.</a>
The <a target="_blank" href="https://www.justice.gov/opa/pr/walgreens-agrees-pay-1068m-resolve-allegations-it-billed-government-prescriptions-never" rel="noreferrer noopener">settlement</a> resolves accusations that the pharmacy chain billed Medicare, Medicaid, and other federal health programs for processed prescriptions but never actually dispensed to beneficiaries.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39555584/walgreens-boots-alliance-expected-to-close-25-of-stores-but-financial-benefit-visib" rel="noreferrer noopener">Walgreens Boots Alliance Expected To Close 25% Of Stores, But Financial Benefit Visible Only Next Year-Analyst</a>.
The alleged fraudulent activity spanned from 2009 to 2020.
The Department of Justice alleges Walgreens collected tens of millions of dollars from the federal government for medications that never reached patients.
As part of the resolution, Walgreens has implemented updates to its electronic pharmacy management system to prevent similar issues from occurring.
Notably, the company received credit for proactively addressing the issue, including self-reporting certain instances and refunding $66.3 million before the settlement.
The settlement also involves significant contributions to individual states, with $14.9 million allocated to Medicaid-participating states. The federal government&#8217;s share of the recovery amounts to $91.9 million.
The settlement covers three cases filed under the qui tam provision of the False Claims Act, allowing private parties to sue on behalf of the government.
Two former Walgreens employees, Steven Turck and Andrew Bustos, were instrumental in these lawsuits. Turck, a former pharmacy manager, will receive $14.9 million, while Bustos, a former district pharmacy supervisor, will be awarded $1.6 million.
In a report, retail pharmacies such as Walgreens Boots Alliance and CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) are becoming less convenient for consumers, as reflected in <a href="https://www.benzinga.com/news/large-cap/24/08/40437498/pharmacy-chains-like-cvs-health-walgreens-boots-alliance-confront-shifting-consumer-habits-and-pro">numerous customer complaints.</a>
Despite their extensive network of locations, frustrations are mounting due to long wait times for assistance and prescription pickups, highlighting the broader issues facing retail pharmacy chains.
Price Action: WBA stock is down 2.5% at $8.98 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40877724/fda-removes-partial-hold-on-zentalis-pharmaceuticals-azenosertib-studies-in-patients-with-gynecol" target="_blank" rel="noreferrer noopener">FDA Removes Partial Hold On Zentalis Pharmaceuticals&#8217; Azenosertib Studies In Patients With Gynecological Cancers</a>.</li>
</ul>
Photo: refrina/Shutterstock.com

Walgreens Agrees To $106.8M Settlement Over Alleged False Billing Claims

Walgreens Boots Alliance's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NYSE">WBA</a>) short percent of float has risen 25.05% since its last report. The company recently reported that it has 82.91 million shares sold short, which is 13.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Walgreens Boots Alliance Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726496112_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Walgreens Boots Alliance has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Walgreens Boots Alliance's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Walgreens Boots Alliance's peer group average for short interest as a percentage of float is 6.29%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Walgreens Boots Alliance's Recent Short Interest

BrightSpring Health Services ("BrightSpring" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>), a leading provider of home and community-based health services for complex populations, today announced that investment funds managed by KKR &amp; Co. Inc. and its subsidiaries ("KKR"), an existing shareholder of BrightSpring, have entered into an agreement with Walgreen Co. ("WBA") to purchase 11,619,998 shares of BrightSpring's common stock from WBA in a private transaction. The transaction was negotiated directly between KKR and WBA, with KKR making the investment through its private equity funds. BrightSpring is not issuing or selling any shares of common stock in connection with the transaction, which is expected to close on or about September 16, 2024.

BTSG

BrightSpring Health Announces That Investment Funds Managed By KKR & Co. And Its Subsidiaries Have Entered Into An Agreement With Walgreen Co. To Purchase 11,619,998 Shares Of BrightSpring's Common Stock From WBA In A Private Transaction

U.S. Announces Walgreens To Pay $106.8M To Settle Allegations Of Billing Government For Undispensed Prescriptions

Deep-pocketed investors have adopted a bullish approach towards Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WBA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Walgreens Boots Alliance. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 3 are puts, totaling $117,441, and 5 are calls, amounting to $262,192.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $9.0 to $12.5 for Walgreens Boots Alliance over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Walgreens Boots Alliance's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Walgreens Boots Alliance's whale activity within a strike price range from $9.0 to $12.5 in the last 30 days. 
<h3>Walgreens Boots Alliance Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726241753_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$0.43</td>
<td>$0.42</td>
<td>$0.43</td>
<td>$9.00</td>
<td>$119.2K</td>
<td>1.9K</td>
<td>2.8K</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$12.50</td>
<td>$55.5K</td>
<td>15.1K</td>
<td>170</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$0.68</td>
<td>$0.64</td>
<td>$0.64</td>
<td>$9.50</td>
<td>$50.6K</td>
<td>1.4K</td>
<td>413</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.38</td>
<td>$0.34</td>
<td>$0.37</td>
<td>$9.00</td>
<td>$37.4K</td>
<td>6.9K</td>
<td>4.1K</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.34</td>
<td>$2.26</td>
<td>$2.33</td>
<td>$10.00</td>
<td>$35.5K</td>
<td>13.3K</td>
<td>185</td>
</tr>
</tbody>
</table>

<h3>About Walgreens Boots Alliance</h3>
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,500 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
Following our analysis of the options activities associated with Walgreens Boots Alliance, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Walgreens Boots Alliance</h3>
<ul>
<li>Currently trading with a volume of 4,952,381, the WBA's price is up by 3.34%, now at $9.13. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 32 days.</li>
</ul>
<h3>Professional Analyst Ratings for Walgreens Boots Alliance</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $12.833333333333334.
<ul>
<li>Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Walgreens Boots Alliance with a target price of $16. </li>
<li>Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Walgreens Boots Alliance with a target price of $15. </li>
<li>Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Walgreens Boots Alliance with a target price of $7. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Walgreens Boots Alliance options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Walgreens Boots Alliance

TD Cowen analyst Charles Ryhee maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Buy and lowers the price target from $22 to $16.

TD Cowen Maintains Buy on Walgreens Boots Alliance, Lowers Price Target to $16

Deep-pocketed investors have adopted a bullish approach towards Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WBA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Walgreens Boots Alliance. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 30% bearish. Among these notable options, 4 are puts, totaling $164,831, and 6 are calls, amounting to $207,934.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $2.5 to $15.0 for Walgreens Boots Alliance over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Walgreens Boots Alliance's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Walgreens Boots Alliance's whale trades within a strike price range from $2.5 to $15.0 in the last 30 days. 
<h3>Walgreens Boots Alliance Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725569266_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.11</td>
<td>$2.1</td>
<td>$2.11</td>
<td>$10.00</td>
<td>$55.9K</td>
<td>18.8K</td>
<td>842</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.44</td>
<td>$0.37</td>
<td>$0.44</td>
<td>$15.00</td>
<td>$48.5K</td>
<td>8.8K</td>
<td>1.1K</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.55</td>
<td>$1.5</td>
<td>$1.51</td>
<td>$7.50</td>
<td>$45.3K</td>
<td>15.0K</td>
<td>405</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$0.79</td>
<td>$0.75</td>
<td>$0.75</td>
<td>$15.00</td>
<td>$34.8K</td>
<td>7.8K</td>
<td>607</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.07</td>
<td>$2.50</td>
<td>$34.5K</td>
<td>102</td>
<td>57</td>
</tr>
</tbody>
</table>

<h3>About Walgreens Boots Alliance</h3>
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,500 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
After a thorough review of the options trading surrounding Walgreens Boots Alliance, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Walgreens Boots Alliance</h3>
<ul>
<li>Trading volume stands at 27,442,682, with WBA's price up by 0.81%, positioned at $8.72.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>Expert Opinions on Walgreens Boots Alliance</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $11.25.
<ul>
<li>An analyst from B of A Securities has decided to maintain their Underperform rating on Walgreens Boots Alliance, which currently sits at a price target of $7. </li>
<li>Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Walgreens Boots Alliance, targeting a price of $15. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Walgreens Boots Alliance, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Walgreens Boots Alliance's Options: A Look at What the Big Money is Thinking

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>On Sept. 4, B of A Securities analyst Allen Lutz maintained Walgreens Boots Alliance with an Underperform and lowered the price target from $11 to $7.5. The company's stock fell around 19% over the past month and has a <a href="https://www.benzinga.com/quote/WBA">52-week low of $8.62</a>.</li>
<li>RSI Value: 25.14</li>
<li>WBA Price Action: Shares of Walgreens fell 3.6% to close at $8.65 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090524&amp;t=be2bearmibe3na1"> latest WBA news.</a> </li>
</ul>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05085714/image-39-1024x483.png" alt="" class="wp-image-531969" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05085714/image-39-1024x483.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05085714/image-39-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05085714/image-39-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05085714/image-39-1536x724.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05085714/image-39.png 1828w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Dollar General Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)&nbsp;</h3>
<ul>
<li>On Aug. 29, Dollar General reported worse-than-expected second-quarter results and lowered its 2024 guidance. The retail behemoth reported second-quarter earnings per share of $1.70, missing the analyst consensus of $1.78. Quarterly sales of $10.21 billion (+4.2% year over year) missed the street view of $10.368 billion.. The company's stock fell around 35% over the past five days. It<a href="https://www.benzinga.com/quote/DG"> has a 52-week low</a> of $79.36.</li>
<li>RSI Value: 16.90</li>
<li>DG Price Action: Shares of Dollar General fell 3.2% to close at $81.08 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090524&amp;t=be2bearmibe3na1"> trend in DG stock. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05062653/image-30.png" alt="" class="wp-image-531526" style="width:669px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05062653/image-30.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05062653/image-30-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05062653/image-30-768x710.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Dollar Tree Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)</h3>
<ul>
<li>On Sept. 4, Dollar Tree reported worse-than-expected second-quarter 2024 earnings. The discount variety stores chain reported an adjusted EPS of $0.67, missing the consensus of $1.04, and down 26.4% year over year. Chief Financial Officer Jeff Davis added, &#8220;Our adjusted EPS of $0.67 was $0.38 below the midpoint of our previous outlook range. While the vast majority of this variance was attributable to an adjustment of our general liability accrual, a portion was attributable to a comp shortfall, which reflected the increasing effect of macro pressures on the purchasing behavior of Dollar Tree&#8217;s middle- and higher-income customers.&#8221;. The company's shares fell around 34% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/DLTR">low of $60.82</a>.</li>
<li>RSI Value: 11.87</li>
<li>DLTR Price Action: Shares of Dollar Tree dipped 22.2% to close at $63.56 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090524&amp;t=be2bearmibe3na1">breakout in DLTR shares. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="877" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05062820/image-31.png" alt="" class="wp-image-531530" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05062820/image-31.png 877w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05062820/image-31-300x289.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05062820/image-31-768x740.png 768w" sizes="(max-width: 877px) 100vw, 877px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40720418/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-7-dividend-yields"> Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

Top 3 Defensive Stocks That Could Lead To Your Biggest Gains In September

B of A Securities analyst Allen Lutz maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Underperform and lowers the price target from $11 to $7.5.

B of A Securities Maintains Underperform on Walgreens Boots Alliance, Lowers Price Target to $7.5

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 10.81%</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and cut the price target from $17 to $12 on July 3. This analyst has an accuracy rate of 74%.</li>
<li>RBC Capital analyst Ben Hendrix maintained a Sector Perform rating and slashed the price target from $22 to $13 on July 2. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On Aug. 19, Walgreens and BARDA announced a strategic partnership to strengthen decentralized clinical trials model and reporting.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://pro.benzinga.com/dashboard">latest WBA news</a></li>
</ul>
<h3 class="wp-block-heading">The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</h3>
<ul>
<li>Dividend Yield: 4.52%</li>
<li>Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and raised the price target from $34 to $35 on Aug. 1. This analyst has an accuracy rate of 63%.</li>
<li>Morgan Stanley analyst Pamela Kaufman maintained an Equal-Weight rating and slashed the price target from $39 to $36 on Nov. 2, 2023. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On July 31, Kraft Heinz reported better-than-expected second-quarter adjusted EPS results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://pro.benzinga.com/dashboard"> trend in KHC stock.</a></li>
</ul>
<h3 class="wp-block-heading">The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>)</h3>
<ul>
<li>Dividend Yield: 3.77%</li>
<li>DA Davidson analyst Brian Holland maintained a Neutral rating with a price target of $121 on Aug. 29. This analyst has an accuracy rate of 67%.</li>
<li>JP Morgan analyst Ken Goldman maintained a Neutral rating and raised the price target from $126 to $128 on Feb. 28. This analyst has an accuracy rate of 81%.</li>
<li>Recent News: On Aug. 28, The J. M. Smucker Company reported upbeat quarterly earnings, but lowered its annual outlook.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in SJM shares</a>.</li>
</ul>

<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Wall Street's Most Accurate Analysts Say Hold These 3 Defensive Stocks With Over 3% Dividend Yields

August saw the <a href="https://www.benzinga.com/news/earnings/24/08/40648231/wall-street-poised-for-strong-start-as-inflation-data-looms-strategist-says-brace-for-volatile-fall">equity market make good the losses</a> it experienced post its mid-July peak, with earnings and benign data helping the fightback. With August in the rearview mirror, here&#8217;s a look at the leaders and laggards among the S&amp;P 500 Index, a broader gauge of market performance.
3-Part Trend: The month&#8217;s trading could be characterized as a tale of three trends. Stocks extended the weakness into August, with the S&amp;P 500 bottoming on Aug. 5, coinciding with the collapse of the global equity markets. The unwinding of the yen carry trades due to the yen&#8217;s strength perked up risk aversion, sending Japanese stocks into a tailspin, and the reverberations became evident elsewhere.
The S&amp;P 500 Index fell 4.3% intraday on Aug. 5, which happened to be a Monday. The collapse was promptly dubbed Black Monday 2.0 to differentiate it from the Black Monday crash of Oct. 1987. The CBOE Volatility Index, commonly called VIX, more than doubled to 65.73 intraday before pulling back. 
On a positive note, the S&amp;P 500 closed off the lows of the day and was down a more modest 3% by the close.
The market saw a steady recovery from the low through Aug. 22, thanks to a slew of catalysts that reinforced expectations that the Federal Open Market Committee would begin cutting rates at its September meeting.
The strong and rapid recovery pushed traders on the defensive, and the market has been moving sideways since then. 
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="819" height="630" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325.png" alt="" class="wp-image-524474" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325.png 819w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325-300x231.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325-768x591.png 768w" sizes="(max-width: 819px) 100vw, 819px" /></figure>
Source: Yahoo Finance
For August, the S&amp;P 500 Index gained 2.28%, ending the month at 5,648.40, off its record closing high of 5,667.20 hit on July 16.
See Also: <a href="https://www.benzinga.com/money/best-growth-stocks">Best Growth Stocks Right Now</a>
The Leaders: None of the Magnificent seven stocks, which have been spearheading the broader market uptrend since the start of the 2023, made it to the list of the top 10 gainers. The list featured two cybersecurity companies, namely CrowdStrike Holdings, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) and Fortinet, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>). CrowdStrike was rebounding from its global-outage-induced slump seen since July 19. 
Fortinet was helped by a strong post-earnings rally.
Two household and personal care products companies also made the cut, while a management change did the truck for coffee chain Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
The top 10 gainers for the month are:
<ul>
<li>Packaged food company Kellanova&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) (+38.62%) (upside primarily due to the rumors of a buyout by privately-held Mars and the subsequent confirmation of the deal)</li>
<li>Fortinet (+32.17%)</li>
<li>Starbucks (+26.52%)</li>
<li>Axon Enterprise, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) (+21.65%); Much of the gains stemmed from a post-earnings bump seen on Aug.7)</li>
<li>Clorox Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) (+21.02%)</li>
<li>CrowdStrike (+19.54%)</li>
<li>Kenvue Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) (+19.88%)</li>
<li>Best Buy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) (+16.04%)</li>
<li>Arch Capital Group Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NYSE">ACGL</a>) (+18.07%)</li>
<li>Progressive Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) (+17.78%)</li>
</ul>
The Laggards: Artificial intelligence server manufacturer Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), which had a dream run after its inclusion in the S&amp;P 500 Index, plummeted following a short report and the delay flagged by the company in filing its 10-K report. Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), which is fraught with fundamental risk, was also one of the worst performers for the month.
A few retailers ended up in the list of the top 10 S&amp;P 500 decliners for August.
The top 10 losers for the month are:
<ul>
<li>Super Micro (-37.62%)</li>
<li>Moderna, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) (-35.08%)</li>
<li>Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) (-31.08%)</li>
<li>Intel (-27.86%)</li>
<li>Walgreens Boots Alliance, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) (-20.19%)</li>
<li>Dollar Tree, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) (-19.02%)</li>
<li>Charles River Laboratories International, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) (-18.99%)</li>
<li>Airbnb, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) (-15.94)</li>
<li>Bath &amp; Body Works, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) (-15.80%)</li>
<li>Etsy, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) (-15.43%)</li>
</ul>
Earnings reactions triggered the weakness seen in some of these stocks, including Intel, and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40139012/moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-c">Moderna, which reduced its full-year forecast.</a>
With the Fed all but decided on a September rate cut, some of these beaten-down stocks, especially those in the retail space, could stage a turnaround. 
The SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that tracks the S&amp;P 500 Index, ended Friday&#8217;s session up 0.95% at $563.68, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40594093/economist-peter-schiff-warns-fed-may-be-committing-mistake-by-lowering-rates-in-sep">Economist Peter Schiff Warns Fed May Be Committing Mistake By Lowering Rates In September As Dollar Index Falls To Lowest In Over A Year</a></li>
</ul>

ABNB

ACGL

AXON

BBWI

CRWD

ETSY

FTNT

GDDY

INTC

KVUE

MPWR

MRNA

SBUX

SMCI

UBER

Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers

Across the recent three months, 14 analysts have shared their insights on Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Walgreens Boots Alliance, presenting an average target of $14.0, a high estimate of $22.00, and a low estimate of $7.00. A 30.73% drop is evident in the current average compared to the previous average price target of $20.21. 
<img src="https://www.benzinga.com/files/images/story/2024/1725040811_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Walgreens Boots Alliance by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$9.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$10.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Walgreens Boots Alliance. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Walgreens Boots Alliance compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Walgreens Boots Alliance's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Walgreens Boots Alliance's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WBA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Walgreens Boots Alliance analyst ratings.</a>
<h2>All You Need to Know About Walgreens Boots Alliance</h2>
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,500 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
<h3>Financial Insights: Walgreens Boots Alliance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Walgreens Boots Alliance showcased positive performance, achieving a revenue growth rate of 2.64% as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Walgreens Boots Alliance's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.95%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Walgreens Boots Alliance's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.54%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Walgreens Boots Alliance's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.41%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Walgreens Boots Alliance's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Walgreens Boots Alliance Through 14 Analysts

JP Morgan analyst Lisa Gill maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Overweight and lowers the price target from $20 to $15.

JP Morgan Maintains Overweight on Walgreens Boots Alliance, Lowers Price Target to $15

Lazard Equity Franchise Portfolio Q2 2024 Commentary

BNY Mellon Income Stock Fund Q2 2024 Commentary

Warning: WBA is at high risk of performing badly

Walgreens: Why I Sold My Position

Top movers as S&P 500 clocks another quarter of growth

Top movers as S&P 500 clocks another quarter of record growth

CVS Health strategic review brings segments into focus

Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3

Walgreens: No Catalysts To Drive A Turnaround

East Coast port strike could be over by Monday, analyst says

AMAT

AMZN

BKAG

BKCI

BKEM

BKGI

BKHY

BKIE

BKLC

BKMC

BKSE

BKUI

BLDR

CBRE

COST

DXCM

ERIE

HELKF

HENKY

HENOF

HENOY

HSIC

LRCX

PLTR

RADCQ

RKLIF

SOLV

XLRE

XRAY

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Walgreens Boots Alliance, Inc. - WBA

Press Releases

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Walgreens Boots Alliance, Inc. (WBA) Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Walgreens Boots Alliance, Inc. (WBA) Investors

Walgreens Announces New Student Loan 401(k) Match Program

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Walgreens Boots Alliance, Inc. (WBA)

Hanley Investment Group Arranges Sale of Single-Tenant Walgreens at Kroger-Anchored Shopping Center in Houston Metro

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Walgreens Boots Alliance, Inc. (WBA)

DEADLINE ALERT for NFE, WBA, DPZ, and BMBL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

BMBL

Albertsons Companies, Inc. Class A Common Stock

Albertsons Companies

Andersons

Sendas Distribuidora

BJ's Wholesale Club Holdings, Inc. Common Stock

BJ's Wholesale Club

Maplebear

Caseys General Stores, Inc. - Common Stock

Casey's General Stores

The Chefs' Warehouse, Inc. - Common Stock

Chefs' Warehouse

Costco Wholesale Corporation - Common Stock

Costco Wholesale

Dingdong (Cayman) Limited American Depositary Shares (each two representing three Ordinary Shares)

Comments

Walgreens Boots Alliance

Notizie

Ultime notizie per Walgreens Boots Alliance (NASDAQ:WBA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO